The National Multiple Sclerosis Society is contributing over 1 million dollars to a Phase II clinical trial that utilizes autologous (the patient’s own) mesenchymal stem cells to treat Multiple Sclerosis (MS). Mesenchymal stem cells were selected for this treatment based on their ability to differentiate into neural progenitor cells, which can serve to repair the damaged neurons that result from MS. The cells are recovered from the patient, then expanded and cultured to differentiate into neural cells in clinically significant numbers.
The cells are then injected back into the spinal fluid, where they secrete growth factors to repair damaged cells, as well as anti-inflammatory factors that researchers believe will inhibit the autoimmune response that causes the neural degeneration in the first place. The 50 patients participating in the trials all have progressive forms of the disease and will be evaluated on neurological and disability scale examinations, in addition to possible adverse effects, but the Phase I has already proven the safety of this treatment.
As regenerative engineering progresses, we believe the best stem cells to use in emerging treatments will be the patient’s own [autologous stem cells] as this negates the need to find a suitable donor and eliminates the chances of rejection of the transplanted tissue. To learn more about banking your own valuable stem cells to insure your family’s future health, visit StemSave or call 877-783-6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here